More than half of Americans have diabetes, but doctors still often prescribe insulin to people who are on insulin.
And now the U.S. Food and Drug Administration has approved a new drug, insulin-like growth factor (IGF), to treat the disorder.
The drug, a combination of IGF-1 and IGF-2, has been on the market for more than a decade.
But the FDA approved the drug last month after the agency found that patients with type 2 diabetes can receive it in less than 24 hours.
The FDA also said it was moving toward approval of the drug for people with type 1 diabetes, which means the drug would go to the market in less time than a year.
The FDA also says it’s moving toward approving the drug in people with Type 1 diabetes.
In fact, it’s one of the reasons why the agency approved the new drug last week.
The news comes amid a growing number of studies that show the drug is a safe and effective treatment for Type 1 and Type 2 diabetes, especially for people who aren’t using insulin.
But patients with Type 2 are less likely to respond to the drug, the FDA said.
The agency also said the drug was not approved for people over 65, as was approved for the drug.
The Drug Enforcement Administration is the main U.N. drug control agency and oversees international trade.
The agency is responsible for enforcing U.